Mozart Therapeutics Raises $25 Million In Expanded Series A Financing To Support Clinical Development Of First-In-Class Cd8 Treg Modulators For The Treatment Of Autoimmune Diseases
Mozart Therapeutics Raises $25 Million In Expanded Series A Financing To Support Clinical Development Of First-In-Class Cd8 Treg Modulators For The Treatment Of Autoimmune Diseases
06/07/23, 12:02 PM
Location
seattleMoney raised
$25 million
Industry
other
health care
Round Type
series a
Investors
Marie Claire Peakman, Alexandria Venture Investments, Altitude Life Science Ventures, Leaps By Bayer, Mrl Ventures Fund, Eli Lilly & Company, Sofinnova Partners, Arch Venture Partners, Upmc Enterprises, Ono Venture Investment, Abb Vie Ventures, Pfizer Ventures, Jasmina Marjanovic, Ph D, Director Abb Vie Ventures, Marie Claire Peakman, Ph D, Partner, Pfizer Ventures
Mozart Therapeutics, a leading developer of CD8 Treg Modulators for the treatment of autoimmune and inflammatory diseases, today announced it has raised $25 million from new investors in a Series A extension, bringing the total raise to $80 million. The proceeds will be used to advance the company's lead candidate, MTX-101, into first-in-human clinical trials and to support pipeline expansion.
Company Info
Location
seattle, washington, united states
Additional Info
Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory immune pathway. The therapeutic focus of Mozart's lead program is autoimmune mediated gastro-intestinal disorders. The company is headquartered in Seattle, WA.